Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives
Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape in the near future.
